A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/70 (2006.01) A61K 35/28 (2006.01) A61K 48/00 (2006.01) C07K 14/82 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2103377
2103377 9222303 PCTABS00018 Leukemias characterized by the presence of the Philadelphia chromosome and the expression of the hybrid bcr-abl gene are treated with antisense oligonucleotides complementary to a target sequence of the bcr-abl mRNA transcript including the breakpoint junction. Individual chronic myelogoneous leukemia patients or Philadelphia chromosome-positive acute lymphocytic leukemia patients are treated by first sequencing the individual's bcr-abl breakpoint junction, and then administering antisense oligonucleotides complementary thereto. The oligonucleotides are designed to hybridize specifically to the bcr-abl breakpoint junction without substantial cross hybridization to untranslocated c-abl sequences. Treatment may comprise in vivo administration of antisense oligonucleotides, or ex vivo treatment such as bone marrow purging.
Calabretta Bruno
Gewirtz Alan M.
Borden Ladner Gervais Llp
Temple University - Of The Commonwealth System Of Higher Educati
LandOfFree
Selective inhibition of leukemic cell proliferation by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective inhibition of leukemic cell proliferation by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective inhibition of leukemic cell proliferation by... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1828869